share_log

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5: Prospectus

Recursion Pharmaceuticals | 424B5：募资说明书
美股sec公告 ·  06/26 16:04
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of $200 million of its Class A common stock. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is subject to completion, dated June 26, 2024. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The offering price is assumed to be equal to the last reported sale price of $9.38 per share as of June 25, 2024, which would result in the offering of approximately 21,321,961 shares. The net proceeds from the offering are intended to fund the advancement of Recursion's existing preclinical and clinical programs, platform technologies, foundation model construction, industrialized validation and translation, scientific and technical personnel, as well as for...Show More
Recursion Pharmaceuticals, Inc. (Recursion) has announced the offering of $200 million of its Class A common stock. The offering is filed under Rule 424(b)(5) with the Securities and Exchange Commission (SEC) and is subject to completion, dated June 26, 2024. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol 'RXRX.' The offering price is assumed to be equal to the last reported sale price of $9.38 per share as of June 25, 2024, which would result in the offering of approximately 21,321,961 shares. The net proceeds from the offering are intended to fund the advancement of Recursion's existing preclinical and clinical programs, platform technologies, foundation model construction, industrialized validation and translation, scientific and technical personnel, as well as for general corporate purposes. The underwriters for the offering are Goldman Sachs & Co. LLC, J.P. Morgan, and Allen & Company LLC, with an option to purchase up to an additional $30.0 million of shares. The prospectus supplement, dated June 2024, provides further details on the offering, including risk factors, use of proceeds, and legal matters.
Recursion Pharmaceuticals, Inc.（Recursion）宣布申购2亿美元的A类普通股。该申购已在2024年6月26日依据424(b)(5)条规以及提交至证券交易委员会（SEC），并将于规定日期完毕。A类普通股在纳斯达克全球精选市场上以“RXRX”为标的进行交易。该发售价格将被视为截至2024年6月25日最近报告的9.38美元/股的成交价格，发售数量将约为21,321,961股。所得款项将用于推进Recursion现有的临床前和临床项目、平台技术、基金会建设模型、工业化验证和翻译、科学和技术人员，并用于一般企业用途。本次申购的承销商为高盛、摩根大通和Allen & Company LLC，还有全额认购3千万美元的额外股票的选择权。2024年6月的招股书补充说明提供了更多关于发售的细节，包括风险因素、用途、法律事项等。
Recursion Pharmaceuticals, Inc.（Recursion）宣布申购2亿美元的A类普通股。该申购已在2024年6月26日依据424(b)(5)条规以及提交至证券交易委员会（SEC），并将于规定日期完毕。A类普通股在纳斯达克全球精选市场上以“RXRX”为标的进行交易。该发售价格将被视为截至2024年6月25日最近报告的9.38美元/股的成交价格，发售数量将约为21,321,961股。所得款项将用于推进Recursion现有的临床前和临床项目、平台技术、基金会建设模型、工业化验证和翻译、科学和技术人员，并用于一般企业用途。本次申购的承销商为高盛、摩根大通和Allen & Company LLC，还有全额认购3千万美元的额外股票的选择权。2024年6月的招股书补充说明提供了更多关于发售的细节，包括风险因素、用途、法律事项等。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息